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Abstract
Endocrine disruptors interfere with endocrine-mediated regulations of cell or organ 
functions. Estrogens are one of the main hormones altered by endocrine disruptors like 
bisphenol A (BPA). Stem cells are active from embryogenesis to late stages of adult life. 
Their unique properties, such as an extended lifespan and low cycling features, render 
these cell privileged targets of long-term exposure to numerous factors. Therefore, stem 
cells are likely to be affected following exposure to endocrine disruptors. One of the 
major signaling pathways involved in stem cell regulation is the bone morphogenetic  
protein (BMP) pathway. The BMP pathway is known for its involvement in numerous 
physiological and pathophysiological processes. Exposure of human mammary stem 
cells to pollutants such as BPA initiates fundamental changes in stem cells, in particular 
by altering major elements of BMP signaling, such as receptor expression and localiza-
tion. Lastly, BPA and its substitute bisphenol S (BPS) have similar impacts on BMP sig-
naling despite their different ER-binding properties, supporting the hypothesis that their 
biological effects cannot be extrapolated only from their interaction with ERα66. We 
review recent discoveries in this field and discuss their implications for cancer diagnosis, 
prevention, and treatment, as well as their relevance for studies on endocrine disruptors.
Keywords: BMP, bisphenol, stem cells, breast cancer, microenvironment,  
endocrine disruptors, estrogen
1. Introduction
Breast cancer is the most common cancer in women and exhibits important phe-
notypic and genetic diversities associated with different prognoses. Breast cancer 
subtypes are clinically classified based on histological appearance and expression of 
hormone receptors such as estrogen (ER) and progesterone (PR) receptors, as well 
as on the amplification of the HER2 gene coding for a member of the EGF receptor 
family [1]. Based on these criteria, four major breast cancer subtypes have been 
defined: luminal A and luminal B (all ER+), HER+ (that can be either ER− or ER+), 
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and basal-like (ER−) [2, 3]. The most frequent subtype encompasses ER-positive 
tumors that represent almost 80% of breast cancers. In these tumors, preventing 
ER activation via hormone therapy is efficient. This can be achieved either by using 
competitive antagonists of estrogens (e.g., tamoxifen), preventing its binding 
to and subsequent activation of ER, by using drugs blocking estrogen synthesis 
(antiaromatase) in postmenopausal women, or by luteinizing hormone-releasing 
hormone (LHRH) analogs, inhibiting release of female hormones by the ovaries [4].
Breast cancer is a multifactorial disease, and evidences of the involvement of 
extrinsic factors in the increase of breast cancer risk have been described, such as 
the environment or lifestyle. Indeed, lack of physical activity, elevated tobacco or 
alcohol consumption, and the use of contraceptive pills or hormone-replacement 
therapy (for postmenopausal women) have been shown to increase breast cancer 
risk [5]. Hormonal status has also been described to play a major role in breast 
cancer risk. It has been shown that a premature or extensive exposure to endog-
enous estrogens (due to an early menarche, nulliparity, late age for first full-term 
pregnancy, or late menopause) increases the risk of breast cancer development.
Several chemical pollutants have been classified as endocrine-disrupting 
chemicals (EDCs) based on the following definition: “an endocrine disruptor is an 
exogenous substance or mixture that alters any function(s) of hormone actions and 
consequently causes adverse health effects in an intact organism, or its progeny, or 
(sub)populations” [6–11]. Estrogens are one of the main hormones altered by EDCs. 
Perturbations in estrogen functions have been identified in a wide spectrum of 
pathologies, including metabolic, bone, and reproductive disorders, as well as breast, 
endometrial, or ovarian cancers. Therefore, it is important to consider that the mam-
mary gland is exposed throughout life not only to endogenous hormones but also to 
EDCs, molecules present in the environment and able to mimic these hormones.
Interest in EDCs is growing rapidly, owing notably to their extensive use in 
manufactured goods and their release in our environment. Among these environ-
mental pollutants, bisphenol molecules are being increasingly studied in breast 
cancer due to their estrogen-mimetic properties, enabling them to activate estrogen 
signaling through their binding to the ER, in particular, bisphenol A (BPA) [12, 13]. 
Despite rising concerns about its safety [14] and progressive restrictions on its use, 
several million tons of BPA are still produced worldwide.
2. The major effects of bisphenols on BMP signaling and stem cells
2.1 BPA and breast cancer
2.1.1 BPA and estrogen signaling
BPA is an aromatic organic compound used by the plastic industry as a monomer 
in the synthesis of polycarbonates and epoxy resins. Polycarbonates are found in 
consumer plastic-like water bottles, food packaging materials, sport equipment or 
toys, while epoxy resins are used to coat the inside of food or beverage containers. 
BPA can also be found in thermal paper. BPA monomers from these compounds 
can be released into the environment by hydrolysis. At the structural level, BPA is 
a diphenyl compound with two hydroxyl groups in a “para” position rendering it 
highly similar to synthetic estrogen (diethylstilbestrol). This thus allows BPA to 
interact with various physiological receptors similar to estrogen, including ERs.
The classical genomic estrogen signaling pathway is triggered by the binding of 
estrogen to its α or β receptors that act as transcription factors in the nucleus. In the 
absence of ligands, these receptors are complexed with inhibitory molecules either 
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in the cytoplasm or in the nucleus of the cell. Upon ligand binding, these complexes 
dissociate resulting in conformational changes that allow DNA binding and recruit-
ment of cofactors to regulate expression of target genes [15]. Both ERα and ERβ are 
also able to initiate a nongenomic signaling pathway outside of the nucleus depend-
ing on their subcellular localization [16]. Moreover, estrogen signaling can also be 
mediated by other receptors, such as GPR30, EGFR, to list only a few [15, 17].
In line with the current definition of EDCs, BPA was shown to exert its activity 
by disrupting the estrogen signaling pathway that uses ER as a transcription factor 
binding to estrogen response element (ERE) sites on DNA [15]. Consequently, 
estrogen-mimetics (e.g., BPA) were mechanistically thought to primarily act 
through their binding to ERα66, the main canonical (nuclear) estrogen recep-
tor. This nuclear receptor initiates signaling pathways at the cell membrane and 
transcriptional responses in the cell nucleus. BPA also upregulates the level of 
steroid receptor coactivators (SRC-1, SRC-3) and promotes the activity of EREs 
[18]. However, BPA has also been shown to bind to a number of distinct nuclear 
and membrane receptors, namely estrogen receptors ERα/β, androgen receptor 
(AR), G protein-coupled ER (GPER, GPR30), PPAR (especially PPARγ), insulin-
like growth factor-1 (IGF1-R) [17, 19, 20]. BPA stimulates the release of EGFR 
ligands by directly targeting other molecules than ER, like ADAM17 or ADAM10 
[21]. Furthermore, the impact of BPA on Ca2+ release or ERK signaling has been 
highlighted in the pancreas [15]. Altogether, these results indicate that BPA, in 
addition to its effects on the canonical estrogen pathway, is able to perturb numer-
ous physiological processes through estrogen genomic and nongenomic signaling, 
as well as nonestrogen-related pathways [19, 22]. Importantly, BPA is at the origin 
of toxic derivatives (chlorinated bisphenols) and is also processed by cellular and 
biochemical mechanisms to generate a number of different BPA metabolites. All 
these BPA derivatives have been reported to have similar or higher toxic effects than 
BPA [19, 20]. In the context of the mammary gland, it is thus of utmost importance 
to further elucidate how BPA, its derivatives or metabolites, modulate estrogen- or 
nonestrogen-related signaling. This should improve our understanding of the 
tumorigenic potential of BPA, firstly in the luminal breast cancer subtype, and 
subsequently in other tumor types.
2.1.2 BPA involvement in breast cancer
Evidence gathered from studies in experimental models and human populations 
has already confirmed that EDCs, including BPA, contribute to increased risk of 
disease [23, 24]. A positive relationship between exposure to BPA and cancer devel-
opment is reported in the literature [25]. However, whether BPA is actually harm-
ful for human health remains understudied, similar to our understanding of the 
molecular mechanisms underlying BPA-dependent effects in cancer development.
Given the significant involvement of estrogens in both normal and patho-
logical conditions, EDCs able to interfere with the homeostasis of the estrogen 
endocrine system are a potential source of several health disorders. In this con-
text, a human population-based study detected a significant increase in serum 
levels of BPA and established a correlation with breast tissue density measured in 
mammographies [26]. This finding was attributed to the ability of BPA to increase 
proliferation of mammary epithelial cells from either normal or breast cancer 
tissues [27, 28]. Epigenetic data from human tumors or cells exposed to BPA in 
vitro revealed the ability of this EDC to directly induce mammary epithelial cell 
transformation [29].
Moreover, BPA was correlated with breast cancer patients with high risk 
profiles and therefore with increased disease relapse [30]. This may be due to the 
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implication of BPA in breast cancer metastasis. This process has traditionally been 
associated with late stages of cancer development, though a new hypothesis on its 
origin has progressively emerged suggesting that it could be an inherent mark of 
tumor cell [31, 32]. Metastatic dissemination is a dynamic process that involves 
several steps: local invasion of cells from the primary tumor, intravasation leading 
to dissemination through the blood or lymph, extravasation to invade new tissues, 
implantation, and finally new tumor growth. Numerous signaling pathways and 
programs are activated during this process such as epithelial-to-mesenchymal 
transition (EMT), anoïkis, migration, and proliferation among others (for review: 
[33, 34]). It has been shown that ER-negative breast cancers are associated with an 
increased risk of developing metastases [35]. Indeed, these breast cancers express 
more mesenchymal markers such as vimentin and N-cadherin or EMT-transcription 
factors that are required for metastatic initiation. Conversely, ER-positive tumors 
are associated with a more differentiated luminal phenotype, expressing epithelial 
markers (E-cadherin, ER, FOXA1 for instance). Accordingly, a downregulation of 
the luminal-specific transcription factor FOXA1 is induced after BPA treatment 
in triple-negative tumor cell lines, leading to the induction of EMT and increasing 
cell motility [36]. In this study, BPA treatment was shown to activate the PI3K/AKT 
pathway, leading to a downregulation of epithelial genes alongside an upregulation 
of mesenchymal genes. Another study demonstrated that BPA promotes migration 
and invasion via GPER, which transduces FAK, Src, and ERK2 signaling pathway 
activation [37]. Promotion of GPER-induced migration by BPA or BPS occurs 
via different signaling pathways. Indeed, in contrast to BPA, which acts via the 
FAK/Scr/ERK2 pathway, it has been shown that BPS induces GPER/Hippo-YAP-
dependent migration [38]. Effects of BPA, BPS, and BPF on migration and EMT 
properties of ER-positive tumor cell lines were compared [39]. After treatment, 
cells lost cell/cell contacts and acquired a fibroblast-like morphology associated 
with an EMT phenotype. This was further confirmed after analysis of EMT-
associated protein expression showing a decrease in E-cadherin and an increase 
in N-cadherin. Moreover, BPA-, BPS-, and BPF-treated cells displayed a stronger 
migratory ability. All of these modifications were inhibited after administration of 
an ER antagonist, demonstrating the ER-dependent effects of these bisphenols [39].
At the mechanistic level, a large number of in vivo and in vitro studies have 
highlighted the ability of BPA to disrupt several key signaling pathways that are 
known to be involved in breast cancer [19, 40]. However, the direct involvement 
of BPA in breast cancer incidence is difficult to establish and remains controversial 
[26, 41], owing possibly to the fact that different mechanisms are depicted in 
either ER-positive or -negative tumors, reflecting the variety of biological effects 
arising from exposure to BPA [20, 28, 42]. In addition, the combinatorial effects 
of different pollutants encountered over a life time also complicate these studies. 
Hence, scientists are faced with a huge challenge in order to formally establish 
the transforming power of BPA, owing to the different contexts and mechanistic 
cascades of alterations occurring in the human breast tissue during such long-term 
exposure.
2.2 BPA target cells
2.2.1 Stem cells in mammary gland
Mammary gland development takes place during embryogenesis and is 
composed of a rudimentary ductal system blocked until puberty. Then, two 
master reproductive hormones are secreted, namely estrogens and progesterone. 
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Estrogens control the growth of ducts from their distal extremity called termi-
nal end buds (TEBs) [43–45], while progesterone is involved in lateral branch 
development [46, 47]. One of the major hormones involved in mammary gland 
development is estrogen, mostly produced by the ovaries (but also by other tis-
sues). Estrogens, in combination with other hormones, orchestrate the growth of 
the ductal system and adipose tissue accumulation during puberty and at further 
stages of development [43–45].
In adults, the mammary gland is formed of ducts and lobules of secreting 
luminal epithelial cells surrounded by contractile myoepithelial cells. These epi-
thelial cells are embedded in a stroma mainly formed of fibroblasts and adipocytes 
that secrete several soluble molecules regulating epithelial cell function and differ-
entiation. Epithelial cells of the mammary gland are generated by mammary stem 
cells (MaSCs) and the stromal compartment by mesenchymal stem cells (MSCs) 
[48–51]. During adulthood, the mammary gland undergoes functional and struc-
tural changes that alternate between phases of proliferation, differentiation, and 
apoptosis controlled by cyclic hormonal variations due to the estrous/menstrual 
cycle modulating the stem cell compartment [52]. However, this postpubertal mam-
mary tree remains immature and only achieves full maturation during pregnancy 
and lactation. These final steps involve alveogenesis and milk production, which 
take place mostly under the control of progesterone and prolactin [53, 54]. Studies 
indicate that estrogens do not directly stimulate proliferation of ER-positive luminal 
cells but act via a paracrine process [55, 56]. Indeed, estrogen acts on luminal ER/
PR-positive cells, leading to the cleavage and liberation of amphiregulin [57, 58], 
which then affects neighboring ER/PR-negative cells. These ER/PR-negative cells 
display characteristics of stem cells, in that, their asymmetric division is controlled 
by growth factors released by stromal cells [59–62]. Conversely, estrogen treatment 
induces a deficient asymmetric division of a human MaSC cell line (MCF10F) [63]. 
Ovariectomized mice (or letrozole treated to inhibit endogenous estrogen synthesis 
and provide a normal stromal and hormonal environment for all other hormones) 
show a decrease in the ability of MaSCs to repopulate a mammary fat pad and to 
generate ductal growth and expansion without impacting the size of the MaSCs-
enriched subpopulation [52]. Collectively, these studies highlight the importance of 
the estrogen pathway on MaSC regulation through direct and indirect effects and 
consequently suggest potential sensitivity of these cells to estrogen-mimetics like 
BPA. Furthermore, stem cells are a unique category of cells active from embryogen-
esis up to late stages of human adult life, and are thus more prone to be exposed to 
EDCs, likely altering their normal functions [64–68].
2.2.2 BPA, stem cells, and breast cancer
It has been shown that exposure to EDCs occurs throughout life and even during 
embryogenesis, at the stage of mammary gland establishment. For instance, BPA 
has been detected in urinary samples but also in maternal and fetal plasma, in colos-
trum, and in placental tissue at birth. Several studies demonstrated that a prenatal 
exposure to BPA induces changes in fetal mouse mammary gland, in the epithelial 
as well as stromal compartments, favoring fat pad maturation and increasing the 
mammary gland susceptibility to carcinogens [69–71]. This is accompanied by 
transcriptome modifications, in particular, an increase in the expression of genes 
belonging to the antiapoptotic family, myoepithelial differentiation, and adipo-
genesis, and a decrease in those involved in cell adhesion [71]. Exposure to BPA at 
puberty alters the function of MaSCs, leading to the appearance in the regener-
ated glands of early neoplastic lesions with molecular alterations similar to those 
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detected in early neoplastic breast cancer tissues [72]. In a physiological model in 
which mice were treated at puberty with BPA, estrogen-dependent transcriptional 
events were perturbed and the number of terminal end buds was altered in a dose-
dependent fashion [27]. In vitro exposure of normal human mammary epithelial 
cells to BPA was shown to induce their proliferation due to the secretion of autocrine 
growth factors and allow them to generate bigger mammospheres [73]. Treated 
cells displayed an increase in DNA hypermethylation of tumor suppressor genes, 
such as Brca1. These data support that BPA can promote early pretumoral stages 
corroborating findings in normal human breast epithelial cells (MCF-10F) [29, 64]. 
Indeed, BPA-treated human MaSC lines, such as MCF-10F, increase their expres-
sion of genes involved in DNA repair and decrease proapoptotic gene expression 
[74]. Chronic exposure of MCF10A cells to BPA at doses similar to those measured 
in contaminated water lead to major MaSC modifications affecting their stem cell 
properties and regulation [64]. Importantly, BPA treatment increases stem-like 
features by inducing the expression of ALDH1 and SOX2 genes, a human MaSCs 
marker and a master regulator of pluripotency in embryonic stem cells, respectively 
[75]. BPA also perturbs signals involved in human mammary stem cell (ERα66 
negative cells) regulation, like the bone morphogenetic protein (BMP) pathway, 
which has been identified in their transformation [76], partly by changing BMP 
membrane receptor availability and priming cells to BMP signaling [64]. These data 
raised the hypothesis that in ER-positive tumors, under tamoxifen treatment and 
in a BPA-containing environment, some cells could acquire resistance to treatment 
by a switch in signaling pathway favoring a stem-like phenotype characterized by 
a decrease in treatment cytotoxicity and a modification of the stoichiometry of the 
type of ER (e.g., an increase in ERRγ or ERα isoform expression).
Overall, these observations strongly support that MaSCs are directly sensitive 
to BPA, which could be involved in their transformation and/or treatment escape 
[27, 72, 74].
2.3 BMP, stem cells, and cancer
2.3.1 BMP and mammary epithelial stem cells
One of the major conserved signaling pathways involved in stem cell regulation 
from embryogenesis up to adult stages is BMP signaling. There are 21 different 
soluble BMP molecules that act through serine/threonine kinase BMP receptors 
(BMPRs). In the context of stem cell regulation, BMP2 and BMP4 are progressively 
emerging as the most important BMPs. The BMP pathway is involved in numerous 
physiological and pathological processes [77]. BMPs control MSC regulation, such 
as lineage specification of adipocytes which are one of the major elements of the 
mammary gland microenvironment [78–80]. Alterations in BMP signaling have 
been implicated in metabolic disorders such as obesity in women [81, 82].
During embryogenesis in mice, BMP4 was shown to participate in the early 
steps of mammary gland development by regulating the dorsoventral axis estab-
lishment [83]. The BMP pathway also plays a role in mammary bud formation and 
outgrowth, as well as in ductal branching morphogenesis initiation. Indeed, BMP4 
is expressed in both mesenchymal and epithelial cells of the mammary bud and the 
use of a BMP4 inhibitor leads to a decrease in bud outgrowth [84]. A link between 
BMPs and progesterone receptor type A involved in branching morphogenesis 
during postnatal mammary gland development has also been shown [85]. In addi-
tion, BMPs are also involved in the myoepithelial compartmentalization and lumen 
formation [85]. The knockout of a BMP extracellular antagonist, Twisted, abrogates 
lumen formation and disorganizes the myoepithelial layer through a decrease in 
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SMAD1-5-8 phosphorylation and the repression of BMP targets (Msx1, Msx2, and 
Gata-3) [86]. In human cells, BMP2 regulates luminal epithelial cells by modulating 
the expression of GATA-3 and FOXA1 [76]. Finally, an in vitro study using sorted 
mouse mammary epithelial undifferentiated cells demonstrated the role of BMP 
signaling in final maturation steps such as lactogenic differentiation [87].
In healthy tissues, epithelial cells, as well as cells within the mammary gland 
environment (fibroblasts, adipose tissue cells, hematopoietic cells), contribute 
to the production of soluble BMP2 and BMP4 molecules [76], while distinct sub-
populations of normal mammary epithelial cells sorted according to CD10 and 
EPCAM expression [88] express different elements of the BMP pathway. A role for 
BMP molecules in MaSC regulation was formally demonstrated by functional assay 
analyses following exposure of different human cell types to soluble BMP2 or BMP4 
[76], and further substantiated by the use of TGF/BMP inhibitors allowing the 
expansion of immature epithelial basal cells [89]. Interestingly, as in the hemato-
poietic system [90], BMP2 and BMP4 molecules have distinct functional effects on 
MaSC regulation despite their strong homology. Indeed, while BMP4 modulates the 
compartment of MaSC and myoepithelial progenitors, BMP2 allows the commit-
ment and proliferation of luminal progenitors [76]. However, the molecular mecha-
nism by which BMPs interact with estrogen signaling to regulate MaSCs remains to 
be further deciphered.
2.3.2 BMP and breast cancer
BMP signaling is also a well-known highly complex pathway that orchestrates 
the development and homeostasis of adult tissues such as the neural system [91]. 
The importance of BMP signaling alterations in cancer stem cell features has been 
revealed in glioblastoma, breast cancer, and leukemia [90, 92–95]. The role of 
BMPs, especially of BMP2 and BMP4, in breast cancer has been largely documented 
[96, 97]. Alterations of BMP ligand expression and signaling have been reported 
and shown to be clinically correlated with breast cancer progression [98, 99] and 
to play a major role in the development of bone metastases [99–101]. Despite the 
fact that BMP4 transcripts are expressed at various levels in tumor tissues or breast 
cancer cell lines [102], high levels of BMP4 are found in 25% of the breast cancer 
tumors displaying a low proliferation index but high recurrence rate [98]. BMP4 has 
crucial functions in promoting tumor growth arrest, migration and metastasis by 
mediating cell cycle arrest in G1 [102], chemokine regulation [103], and inhibition 
of lumen formation [104] for example. However, the biological effects of BMP4 
largely depend on cell context, as they were reported to be either proliferative or 
antiproliferative in mammary epithelial cells according to cellular density and coop-
erative factors [105, 106]. The microenvironment of human primary luminal breast 
tumors produces abnormally high amounts of soluble BMP2 compared to healthy 
tissue, while higher BMPR1B levels were detected in tumor cells [76, 107]. Chronic 
exposure to high BMP2 concentrations was demonstrated to initiate MaSC trans-
formation toward a luminal tumor phenotype dependent on a BMPR1B-initiated 
signaling cascade involved in luminal commitment of normal MaSC. This leads to 
a FOXA1/FOXC1 transcription factor balance switch in favor of FOXA1, simultane-
ously with an upregulation of GATA3 [76]. However, while an increase in soluble 
BMP2 in the tumor microenvironment has been shown in luminal ER-positive 
tumors where it is correlated with a high BMPR1B tumor expression [76], a strong 
decrease in BMP2 transcripts was found in ER-negative breast tumors [108]. Also, 
a downmodulation of the BMPR1B (Alk6) in a basal cell line (MDA-MB-231) 
increased cell growth in vitro [109], suggesting an antiproliferative function for 
BMPR1B in ER-negative tumors. Interestingly, downregulation of BMPR1A (ALK3) 
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in MDA-MB231D (a bone metastatic clone of MDA-MB231) basal ER-negative cells 
inhibited their migration and bone metastatic properties [110]. Therefore, it is very 
likely that the BMP2/BMPR1B signal is overactivated in the context of ER-positive 
tumors, while being repressed in ER-negative tumors.
Some of the first steps of carcinogenesis are an increase in proliferation, eva-
sion of apoptosis, and activation of survival signaling pathways. To achieve this, 
several tumor suppressor genes, like p53 or BRCA1 for instance, need to be inacti-
vated by different mechanisms including epigenetic changes. Modulation of BMP 
signaling by epigenetic mechanisms [111], such as methylation of BMP-receptor 
promoters, has been of particular clinical interest to further stratify glioblastoma 
patients and propose new therapeutic strategies [92]. While different genetic 
alterations progressively appear following different oncogenic signals, heredity 
likely accounts for only 10–30% of breast cancers. Based on epidemiological stud-
ies, different factors increasing the risk of breast cancer development have been 
highlighted. They can be intrinsic, like mutations in BRCA1 or 2, Tp53, ATM, or 
also PTEN, or extrinsic, like environmental factors or lifestyle [112, 113]. In breast 
cancers with a genetic origin, the most commonly mutated genes are BRCA1 and 
BRCA2, associated with an increase in cancer risk. BRCA1 and 2 are two major 
regulators of double-strand breaks (DSB) DNA repair through homologous recom-
bination (HR) and play a crucial role as tumor suppressor genes. In this context, it 
is interesting to note that a family member and negative regulator of P53, DNp63 
has been reported to mediate activation of BMP signaling in order to govern 
epithelial cell plasticity, EMT, and tumorigenicity during breast cancer initia-
tion and progression [114, 115]. DNp63 has also been identified as a repressor of 
BRCA1 expression exclusively in ER-positive breast cancer cells [116]. Moreover, 
a correlation between the BMP pathway and the P53-ATM signaling has been 
reported [117]. However, the importance of these different signaling crosstalks in 
the context of breast cancer, exposure to EDCs, and stem cell transformation need 
to be investigated.
2.4 BMP, estrogen, and bisphenols
2.4.1 BMP and ER crosstalk
The BMP signaling pathway is a dynamic and complex pathway, leading to the 
transduction of various signals depending on the nature of the BMP ligand and of 
the BMPR complex oligomerization induced (for review: [118, 119]). It has been 
shown that BMPs may interact with their receptors in two different ways [120, 121]: 
on the one hand, BMPs induce a BMPR complex formation called BISC (BMP-
induced signaling complex), and on the other hand, a preformed BMPR complex 
is present before BMP fixation, known as PFC (preformed complex). These two 
different modes of BMP signal initiation lead to two different signaling cascades, 
namely the canonical SMAD-dependent pathway and the noncanonical SMAD-
independent pathway [121]. SMAD-phosphorylated proteins then form a complex 
with SMAD4, leading to its translocation to the nucleus where it acts as a transcrip-
tion factor on target genes [118, 122]. The SMAD-independent pathway does not 
simply encompass one signaling pathway but a multitude of downstream cascades, 
involving p38, Ras/ERK, and PI3K/AKT [123–126]. Interestingly, SMAD1-5-8 phos-
phorylation is more abundant in undifferentiated murine progenitors and decreases 
with their differentiation until it is almost fully abrogated in the differentiated cells 
treated with prolactin [87]. Involvement of the BMPR1A/SMAD1-5-8 pathway 
in lactogenic differentiation was further confirmed by the lack of expression of a 
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lactogenic differentiation marker (beta-casein) at the RNA and protein levels in 
BMPR1A knockdown mammary cell lines [87]. These data demonstrate that the 
BMP pathway constitutes an important regulator of the mammary gland during 
embryogenesis but most likely also during adulthood. However, the molecular and 
functional crosstalk between the BMP and estrogen signaling pathways is poorly 
understood. A first set of experiments describes the repression of BMP signaling by 
ER inhibition of BMP production through a direct interaction between SMAD1  
and ER [127]. Reciprocally, a BMP2 signal was shown to upregulate the expres-
sion of ER receptors, including the induction of specific ER isoforms such as 
ERα36 [128, 129]. Interestingly, crosstalk between BMP4 and estrogen signaling 
seems to have opposite effects. Indeed, BMP4 inhibits ERα signaling by promot-
ing receptor degradation through the proteosomal pathway, while estrogens 
repress BMP4 expression [130]. Similarly, estrogen represses BMP4 expression in 
cardiomyocytes by preventing BMP4-mediated ERβ expression and JNK activity 
in this system [131]. In addition, in this context, estrogen inhibition of BMP4 is 
independent of Smad1/5/8 activity [131]. BMP4, upon activation of its canonical 
pathway, represses CYP17A1 and induces the transcription of CYP19A1, involved 
in androgen and estrogen synthesis, respectively [132]. In a rat model of pituitary 
cells, estrogen stimulates the transcriptional activity of BMP4-specific SMADs 
through an ER-SMAD1 complex shown to stimulate prolactin production, while 
having no effect on the TGFβ/SMAD pathway [133]. Similarly, the inhibitory effects 
of estrogen signaling on the BMP pathway appear to be mediated by a direct physi-
cal interaction between ER receptors and the SMAD1 BMP signaling element in a 
luminal breast cancer cell line model (MCF7). The physical interaction between ERα 
and SMAD1 requires the DNA binding domain of ERα and this complex formation 
is dependent on BMP2 and estrogen [127]. Moreover, BMP signaling has also been 
directly identified in thyroid-lineage specification [134, 135] as well as in thyroid 
carcinoma [136]. Interestingly, thyroid hormone status interferes with estrogen 
target gene expression in breast cancer samples in menopausal women [137]. These 
findings highlight the need to further investigate the importance of the BMP path-
way in both thyroid and estrogen signaling in a broader context of exposure to EDCs.
More recently, BMP2-mediated luminal transformation of MCF10A was shown 
to be accompanied by a strong activation of the estrogen signaling pathway despite 
the absence of ERα66 in those cells [76]. Our understanding of estrogen signaling is 
hindered by the existence of several isoforms generated by alternative splicing and 
different promoter usage [138]. Interaction of these isoforms with the BMP signaling 
elements has not yet being investigated but could be involved in epithelial stem cell 
response to BMP2. Indeed, the importance of these different ERα isoforms in mam-
mary epithelial SC features and in the context of breast cancer is only just starting to 
be identified [139, 140]. These isoforms can be expressed in both ERα66-positive and 
-negative cells and display different subcellular localizations [141, 142]. For example, 
unlike ERα66, ERα36 is expressed mainly at the plasma membrane and activates 
estrogen nongenomic signaling by activating the ERK pathway through an interplay 
with the MKP3 phosphatase [143]. Interestingly, in the context of EDC research, 
ERα36 displays altered ligand preference and causes distinct effects compared to 
ERα66. For instance, the tamoxifen drug used as an estrogen antagonist in ERα66 
breast cancers behaves as an estrogen agonist for ERα36 [140, 144]. Collectively, 
these different examples illustrate how BMP signaling through its interaction with 
estrogen signaling is at the crossroad of a number of fundamental physiological 
processes. The BMP pathway is therefore directly involved in mammary stem cell 
regulation and transformation, yet adverse effects of EDCs, like BPA, on the BMP 
pathway have not been thoroughly investigated (Figure 1).
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2.4.2 BMP and bisphenols
Works from our team and others suggest that bisphenols could act on multiple 
cell types of the mammary gland, and their effects may converge to provoke major 
dysregulations of the BMP pathway that could contribute to luminal breast cancer 
initiation. Indeed, we observed a major impact of BPA on the mammary microen-
vironment (niche) equilibrium. BPA greatly increases BMP2 production by stromal 
cells of the human mammary SC microenvironment reaching levels comparable 
to those measured in luminal breast cancer [76]. Moreover, BPA treatment leads 
to a decrease in estrogen and BMP15 production in oocytes delaying their matura-
tion [145]. A decrease in BMP2 production through a direct binding of BPA to 
ERγ was involved in bone loss through a suppression of osteoblast differentiation 
reverted by inhibition of ERγ [146]. This suggests that the effects and mechanisms 
of BPA-induced BMP ligand production depend on the estrogen receptor expres-
sion profile and are context dependent [147]. However, the molecular mechanism 
by which BPA induces BMP2 production by stromal cells of the mammary gland 
BMP2 is not yet known. On the other hand, we have demonstrated that long-term 
exposure (60 days) to BPA initiates fundamental changes in human mammary 
stem cells themselves, in particular, by altering major BMP signaling elements such 
as receptor expression and localization [64]. This results in the “priming” of stem 
cells to exogenous activating signals of the BMP pathway and sensitizes them to be 
more sensitive to exogenous soluble BMP ligands. We then demonstrated for the 
first time that nongenotoxic alterations of both the stem cells and their niche act 
Figure 1. 
Illustration of the main findings that show a crosstalk between BMP and estrogen signaling pathways.
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synergistically to initiate a transforming process mediated by the BMP signaling 
perturbation leading to the emergence of ER-positive tumors [76]. Interestingly, 
these previous studies showed that BPA impacts BMP signaling pathway members 
in both mammary epithelial and stromal cells that do not express ERα66. At the 
mechanistic level, the pathways used by BPA to induce these effects in cells remain 
to be deciphered, focusing notably on their reliance on other ERα isoforms or on 
ER-independent factors.
These questions are of great interest for understanding the effects of both BPA 
and estrogens since it has been reported that some cell lines respond to an estrogen 
signal despite their very low levels or complete absence of ER [148]. In response 
to accumulating evidence in favor of adverse health effects following exposure to 
BPA, likely mediated by its activation of ERα66, alternative bisphenols have been 
developed such as BPS and BPF that are considered safer due to their very low bind-
ing affinity to ERα [149–151]. However, an increasing number of studies show that 
these alternative bisphenol molecules are not as innocuous as anticipated, includ-
ing an impact on obesity, steatosis, and reproduction [20]. In a study previously 
conducted in our team, assessing the impact of bisphenol on BMP2 production by 
stromal cells of the mammary gland, we were surprised to observe that BPA and 
BPS displayed very similar effects [76]. Indeed, both BPA (high affinity binding to 
estrogen receptors) and its substitute BPS (very weak affinity binding to estrogen 
receptors) induce BMP2 synthesis in the healthy breast stroma, raising concerns 
as to whether these bisphenols mediate their transforming effects solely through 
a classical ER-dependent mechanism. Since then, other studies have shown that 
BPS, as well as BPF, induces similar if not more potent effects than BPA [20, 152, 
153]. Moreover, it was reported that BPA treatment increases aromatase expres-
sion and its activity in healthy breast fibroblasts, leading to an increase in estrogen 
biosynthesis and secretion. The same observations were made after treatment with 
BPS [154]. These results are of particular interest with regards to the important role 
of the microenvironment in the different steps of carcinogenesis and in the context 
of MaSC-driven transformation by BMP signaling. Our work thus indicates that 
the BMP pathway could be altered by several EDCs such as BPA and its proposed 
alternatives, both at the level of stem cells and their microenvironment. This sug-
gests that early detection of increased BMP2 levels in the mammary microenviron-
ment may constitute a reliable marker of early transformation process and could 
be a valuable indicator of exposure to EDCs such as bisphenols. In addition, the 
interplay between BMP and estrogen pathways both at the molecular and functional 
levels prompt us to further decipher the mechanisms underlying bisphenol- and 
BMP-induced transformation in mammary epithelial stem cells.
3. Conclusions
Different signaling pathways often engage in complex interactions synergisti-
cally mediating an appropriate cellular response. Estrogen signaling is no exception 
and it is likely involved in a crosstalk with the BMP pathway at multiple levels in the 
mammary gland. BMPs are secreted proteins active in a very large number of organs 
and tissues during development, adulthood, and pathogenesis [155]. Previous work 
suggested a close interaction between ER-mediated estrogen signaling and the BMP 
pathway in different cell types of the mammary gland. In a model of mammary epi-
thelial stem cells, E2 or known EDCs like BPA or BPS were able to potentiate SMAD 
activation by BMP2 [64]. This was possibly due to a physical interaction between 
ERα isoforms and SMAD factors, such as that reported for ERα or ERβ, and could 
be associated with an increased risk of cell transformation by long-term exposure 
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to BMP2. Deciphering the dysregulations of the BMP signaling pathway has been 
remarkably useful in identifying its importance in cancer stem cell phenotypes in 
the neural system [92, 93]. The role of alterations of BMP signaling to sustain cancer 
stem cell features has been extended by us and others in breast cancer and leukemia 
[90, 94, 95]. We showed that chronic exposure to high concentrations of BMP2 
drives the transformation of mammary stem cells toward the luminal tumor subtype 
[76] through binding to its BMPR1B receptor. However, downstream mechanisms 
and crosstalks with estrogen signaling in those mammary stem cells remained to be 
understood. This is especially important in the context of several studies that dem-
onstrated the involvement of BPA in the proliferation of either ER-positive or -nega-
tive cancer cells. In addition, BPA can trigger proliferation via nonclassical estrogen 
receptors, including the estrogen-related receptor gamma (ERRγ) [156, 157]. We also 
demonstrated that long-term exposure of human mammary stem cells (ER-negative 
in terms of ERα-66 expression) to pollutants such as BPA initiates fundamental 
changes in stem cells by altering major BMP signaling components [64], thus 
“priming” stem cells to exogenous BMP activation. Complementary to this effect on 
epithelial stem cells, we revealed an impact of BPA on the tumor microenvironment 
through the induction of the synthesis of high levels of BMP2 by normal fibroblasts 
and stromal cells reaching levels similar to those measured in breast tumors [76].
Resistance and relapse can be due to tumor adaptation or evolution. Indeed, 
therapies elicit a selective pressure on cells, which in turn develop resistance, 
notably by acquiring mutations. Resistance to tamoxifen of ER-positive tumors can 
be caused by a loss of ER [158], its mutation, or posttranslational modification [159] 
among others. It was shown that BPA is involved in chemoresistance [160] and 
notably in resistance to tamoxifen in ER-positive tumor cell lines [161] by decreas-
ing tamoxifen-induced apoptosis and increasing gene expression of ERRα, which 
contributes to resistance to tamoxifen [162] and cell proliferation [157]. Another 
study demonstrated that an ERα variant could be induced by BMP2 [128] and may 
be involved in resistance to tamoxifen [163]. The addiction of cancer cells toward 
BMP signaling and the crosstalk with estrogen signaling is currently under consid-
eration as a new therapeutic avenue for ER-positive breast cancer patients [164]. At 
the clinical level, targeting estrogen signaling has been decisive in improving the 
outcome of ER-positive breast cancer patients. At the era of immunotherapy, the 
analysis of the impact of bisphenols on the immune system and on tumor surveil-
lance is crucial. This will need to be pursued to improve our understanding and 
implementation of antiestrogen therapies in the context of their combination with 
new immune treatments [165]. Overall, these data indicate that disruption of BMP 
signaling affects both the stem cells and their niche at different stages of the disease, 
which could be instrumental in the management of breast cancer.
Several studies demonstrated that BPS promotes breast cancer cell proliferation, 
notably through an ER-cyclin D1-CDK4/6-pRb-dependent pathway, exclusively in 
ER-positive breast cancer cells [38, 39, 166]. Moreover, it has also been demonstrated 
that BPF has the same proliferative action as BPA, BPS, or estrogen treatments on 
transformed ER-positive cells. Similar to BPS, this proliferative effect relies on cyclin 
D and E expression through ER-dependent pathways [39]. BPS, as shown for BPA, 
can also induce epigenetic and transcriptional changes in breast cancer cells, resulting 
in an increase in the expression of genes implicated in proliferation, cellular attach-
ment as well as adhesion and migration [167]. Lastly, the bioavailability of BPS substi-
tutes might be higher than for BPA. A recent study conducted in pigs, an ideal model 
for mimicking the human digestive tract, demonstrated the lower plasma clearance 
of BPS (3.5 lower) compared to BPA and an increased oral systemic exposure exceed-
ing 250-fold [168]. These observations draw our attention and raise concerns about 
replacing BPA by BPS, as this may result in an increased internal exposure to EDCs.
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To conclude, BMP signaling plays a major role in the regulation of SCs and of their 
microenvironment (niche), in both normal and tumor contexts. Multiple abnormali-
ties of BMP signaling have been observed in cancer, but until recently studies had 
mostly focused on its role in advanced disease. However, due to the number of studies 
describing the importance of BMP signaling throughout breast cancer development 
(from initiation, progression, metastasis up to resistance), we suggest that early 
detection of BMP signaling alterations, such as increased levels of BMP2 and/or of 
BMP receptors, may constitute a reliable marker of exposure to BPA. This suggests 
that further investigations into alterations of the BMP pathway in the context of 
exposure to bisphenols should improve our understanding of associated side effects.
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